Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders

Authors

  • Gábor Mátyás,

    Corresponding author
    1. University of Zurich, Institute of Medical Genetics, Division of Medical Molecular Genetics and Gene Diagnostics, Zurich, Switzerland
    • Division of Medical Molecular Genetics and Gene Diagnostics, Institute of Medical Genetics, University of Zurich, Schorenstrasse 16, CH-8603 Schwerzenbach, Switzerland
    Search for more papers by this author
  • Eliane Arnold,

    1. University Children's Hospital, Division of Metabolism and Molecular Pediatrics, Zurich, Switzerland
    Search for more papers by this author
  • Thierry Carrel,

    1. University Hospital, Clinic for Cardiovascular Surgery, Berne, Switzerland
    Search for more papers by this author
  • Daniela Baumgartner,

    1. Innsbruck Medical University, Department of Pediatric Cardiology, Innsbruck, Austria
    Search for more papers by this author
  • Catherine Boileau,

    1. Université Paris 5, Institut National de la Santé et de la Recherche Médicale U781, Hôpital Necker-Enfants Malades, Paris, France
    2. Université Versailles-Saint-Quentin-en-Yvelines, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Laboratoire de Biochimie, d'Hormonologie et de Génétique Moléculaire, Boulogne, France
    Search for more papers by this author
  • Wolfgang Berger,

    1. University of Zurich, Institute of Medical Genetics, Division of Medical Molecular Genetics and Gene Diagnostics, Zurich, Switzerland
    Search for more papers by this author
  • Beat Steinmann

    1. University Children's Hospital, Division of Metabolism and Molecular Pediatrics, Zurich, Switzerland
    Search for more papers by this author

  • Communicated by Mark H. Paalman

Abstract

Very recently, heterozygous mutations in the genes encoding transforming growth factor beta receptors I (TGFBR1) and II (TGFBR2) have been reported in Loeys-Dietz aortic aneurysm syndrome (LDS). In addition, dominant TGFBR2 mutations have been identified in Marfan syndrome type 2 (MFS2) and familial thoracic aortic aneurysms and dissections (TAAD). In the past, mutations of these genes were associated with atherosclerosis and several human cancers. Here, we report a total of nine novel and one known heterozygous sequence variants in the TGFBR1 and TGFBR2 genes in nine of 70 unrelated individuals with MFS-like phenotypes who previously tested negative for mutations in the gene encoding the extracellular matrix protein fibrillin-1 (FBN1). To assess the pathogenic impact of these sequence variants, in silico analyses were performed by the PolyPhen, SIFT, and Fold-X algorithms and by means of a 3D homology model of the TGFBR2 kinase domain. Our results showed that in all but one of the patients the pathogenic effect of at least one sequence variant is highly probable (c.722C>T, c.799A>C, and c.1460G>A in TGFBR1 and c.773T>G, c.1106G>T, c.1159G>A, c.1181G>A, and c.1561T>C in TGFBR2). These deleterious alleles occurred de novo or segregated with the disease in the families, indicating a causative association between the sequence variants and clinical phenotypes. Since TGFBR2 mutations found in patients with MFS-related disorders cannot be distinguished from heterozygous TGFBR2 mutations reported in tumor samples, we emphasize the importance of segregation analysis in affected families. In order to be able to find the mutation that is indeed responsible for a MFS-related phenotype, we also propose that genetic testing for sequence alterations in TGFBR1 and TGFBR2 should be complemented by mutation screening of the FBN1 gene. Hum Mutat 27(8), 760–769, 2006. © 2006 Wiley-Liss, Inc.

Ancillary